Prof Frank Griesinger, medical oncologist at Pius Hospital, Oldenburg, Germany presents real-world data and outcomes in the US and Germany after first-line treatment with osimertinib  in patients with EGFRm advanced NSCLC.

With the educational support of:

You may also be interested in:

The new TNM classification for lung cancer

Updated safety data of AEGEAN study

Two good options for patients with stage III NSCLC

Tags:

poster